Our expert panel meticulously reviewed the preclinical and clinical data presented and offered valuable insights into emerging trends and promising future milestones as the landscape continues to gain momentum. Watch the recording now.
Speak with our team about Beacon DDR
What is Beacon DDR?
Beacon DNA Damage Response (DDR) covers trial and drug records for clinical, preclinical, approved, and discontinued therapeutics targeting key points in DNA damage response pathways.
New data expansion: Deals and Companies. Gain unparalleled access to in-depth company profiles and the latest commercial deals. Monitor your competitors and opportunities as well as benchmark deals and evaluate potential partners. Learn more about Deals and Companies data by downloading the factsheet.
How Beacon DDR Works
Search the trial and drug landscape by target, repair pathway and mechanism of action alongside 15 other search criteria including disease, line of therapy, biomarker, sponsor, plus more, to instantly extract the data points you need to conduct more complex analyses.
Our unique Milestones filter and visualization highlights past, present, and future drug development milestones including drug and trial readouts, asset history, and regulatory announcements. This enhancement provides an accurate, timely and exhaustive single-drug timeline allowing you to benchmark progress in the DDR space.
What is Beacon?
Beacon is a world-leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
